Thus, we conclude that BBR may be a promising adjuvant for overcoming TRAIL resistance in TRAIL/DR5-targeted therapy by sensitizing breast cancers to TRAIL/DR5-induced apoptosis. This evidence concerns the gene TNFRSF10B and breast carcinoma.